PRDM15表达水平与头颈鳞状细胞癌预后的关系

目的 探讨PRDM15在头颈鳞状细胞癌(HNSCC)中的表达与预后的关系.方法 利用免疫印迹和免疫组化检测HNSCC及癌旁组织样品中PRDM15的表达.分析PRDM15表达与临床病理资料和生存时间的关系.结果 与癌旁组织相比,PRDM15蛋白在HNSCC癌组织中高表达.与低表达PRDM15的HNSCC患者相比,PRDM...     

雷帕霉素联合顺铂对CCL19调节头颈鳞状细胞癌细胞活性的影响

Objective To investigate the synergistic effects of rapamycin and cisplatin on head and neck squamous cancer cells regulated by chemokine( C-C motif) ligand 19 (CCL19). Methods The role of rapamycin and cisplatin was detected on cell-cycle and apoptosis in CCL19 induced PCI-4B and PCI-37B cells by methyl thiazolyl tetrazolium (MTT) and flow cytometry(FCM). Dose-effect relationship parameters and combination index(CI) were calculated on the median-effect equation and multiple drug effect equation using computer software CalcuSyn. Statistical analysis was performed by the unpaired student's t-test.Results Rapamycin and cisplatin could respectively increase the growth arrest, the proportion of G1 phase and apoptosis of CCL19 induced cancer cells (P ＜0. 05 ). Under inhibitory concentration 50% (IC50), CI was less than 1, and in IC75, it was more than 1 in PCI-4B cells. In PCI-37B cells, under IC75, CI was less than 1, and in IC90, it was more than 1. Conclusions Rapamycin and cisplatin can inhibit CCL19-regulated PCI-4B and PCI-37B cells' survival. The two drugs have synergistic effects when used in combination.     

趋化因子受体7小干扰RNA对人头颈部鳞状细胞癌细胞增殖及侵袭的影响

目的 研究趋化因子受体7(chemokine receptor7,CCR-7)小干扰RNA(small interfering RNA,siRNA)高表达的人头颈部鳞状细胞癌(squamous cell carcinoma of head and neck,SCCHN)细胞系PCI-4B增殖和侵袭能力的影响,探讨siRNA技术在SCCHN基因治疗中的可行性和特异性.方法 选用阳离子脂质体LipofectamineTM 2000作为转染试剂,将针对人CCR-7基因的siRNA转染PCI-4B,采用Western blotting法检测CCR-7蛋白水平,应用甲基噻唑基四唑(MTT)法检测转染前后细胞增殖变化,应用激光共聚焦显微镜观察细胞的改变,Transwell趋化小室法检测细胞体外侵袭能力的改变,并通过荧光显微镜及TransAMTM细胞核因子西乙蛋白(nuclear favor-kappa B,NF-Κb)p65活性检测试剂盒检测NF-Κb细胞内定位及活性.结果 CCR-7 siRNA转染后,细胞内CCR-7蛋白表达水平显著降低(P＜0.05);CCL-19诱导使SCCHN细胞增殖能力增高,细胞极性浓聚、迁移和侵袭能力增高、NF-Κb活化及核转位,这些效应均被CCR-7 siRNA抑制.结论 CCR-7 siRNA在体外成功地下调CCR-7的蛋白水平,抑制了CCL-19增强PCI-4B增殖能力和迁移能力的效应,为临床SCCHN的治疗提供了新方法.